Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)

NCT ID: NCT00866294

Last Updated: 2017-01-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 416 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-04-30
• Study Completion Date: 2010-02-28

Brief Summary

This is a randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of controlled-release (CR) formulation of paroxetine orally administered to patients with major depressive disorder (MDD) at a dose level in the range of 25 - 50 mg/day (initial dose level, 12.5 or 25 mg/day) once daily after evening meal for 8 weeks based on the decrease in HAM-D (Hamilton Depression Rating Scale) total score, to evaluate the safety based on adverse events, laboratory data and vital signs, and to describe the efficacy and safety of immediate release (IR) formulation of paroxetine.

Conditions

Depressive Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

paroxetine CR group

controlled-release (CR) of paroxetine 12.5 to 50mg/day

Group Type: EXPERIMENTAL

matched placebo to paroxetine IR 10mg or 20mg

Intervention Type: DRUG

1 or 2 tablets once a day

Paroxetine CR 12.5mg tablet

Intervention Type: DRUG

1 or 2 tablets once a day

Paroxetine CR 25mg tablet

Intervention Type: DRUG

1 or 2 tablets once a day

matched placebo to paroxetine CR 12.5mg or 25mg

Intervention Type: DRUG

1 or 2 tablets once a day

paroxetine IR group

Immediate-release (IR) of paroxetine 10 to 40mg/day as a reference arm

Group Type: OTHER

paroxetine IR 10mg tablet

Intervention Type: DRUG

1 or 2 tablets once a day

paroxetine IR 20mg tablet

Intervention Type: DRUG

1 tablet once a day

matched placebo to paroxetine IR 10mg or 20mg

Intervention Type: DRUG

1 or 2 tablets once a day

matched placebo to paroxetine CR 12.5mg or 25mg

Intervention Type: DRUG

1 or 2 tablets once a day

placebo group

matched placebo to both paroxetine CR and paroxetine IR

Group Type: PLACEBO_COMPARATOR

matched placebo to paroxetine IR 10mg or 20mg

Intervention Type: DRUG

1 or 2 tablets once a day

matched placebo to paroxetine CR 12.5mg or 25mg

Intervention Type: DRUG

1 or 2 tablets once a day

Interventions

paroxetine IR 10mg tablet

1 or 2 tablets once a day

Intervention Type: DRUG

paroxetine IR 20mg tablet

1 tablet once a day

Intervention Type: DRUG

matched placebo to paroxetine IR 10mg or 20mg

1 or 2 tablets once a day

Intervention Type: DRUG

Paroxetine CR 12.5mg tablet

1 or 2 tablets once a day

Intervention Type: DRUG

Paroxetine CR 25mg tablet

1 or 2 tablets once a day

Intervention Type: DRUG

matched placebo to paroxetine CR 12.5mg or 25mg

1 or 2 tablets once a day

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

<at the start of placebo run-in phase> Only the patients who meet all of the following conditions at Week -1 (at the start of placebo run-in phase) will be enrolled in this study. The hospitalization status will be no object. and Gender: No object.

• Target disease: Patients diagnosed as having one of the following depressive disorders based on DSM-IV-TR classification in conjunction with M.I.N.I. (The Mini International Neuropsychiatric Interview, Japanese version 5.0.0. [2003]) and showing currently a symptom of depression or depressed sate
• Major depressive disorder, single episode (296.2) (excluding those accompanied by comorbid psychiatric disorders)
• Major depressive disorder, recurrent (296.3) (excluding those accompanied by comorbid psychiatric disorders)
• Age: >= 20 years (at the time of obtaining consent)
• Consent: Patients from whom written consent to participate in this study can be obtained
• Gender:
• Female patients of childbearing potential can be enrolled. But, such patients who can be enrolled are limited to only those who are negative in the pregnancy test performed at the start of the placebo run-in phase and who agree to receive a pregnancy test at the time point defined in the study period and surely perform any of the contraceptive methods.
• Male subjects must abstain from (or use a condom during) sexual intercourse with a pregnant or lactating female. Male subjects must abstain from or use a condom plus spermicidal agent (foam/gel/film/cream/suppository) during sexual intercourse with a female of child-bearing potential.
• Patients whose HAM-D (17 items) total score is >= 20 points
• Patients whose duration of current episode at least 12 weeks but no longer than 24 months
• Patients whose score of "depressed mood" (HAM-D Item 1) is >= 2 points
• QTc<450 millisecond (msec) or <480 msec for patients with Bundle Branch Block - values based on either single ECG values or triplicate ECG averaged QTc values obtained over a brief recording period.

For the purposes of these criteria, QTc B (Bazett's correction) is defined as (QT interval [msec]) /(square root of RR interval [seconds])

<at the start of treatment phase> Only the patients who meet all of the following conditions at Week -1 (at the start of the placebo run-in phase) and Week 0 (at the start of treatment phase) can be shifted to the treatment phase.

• Patients whose HAM-D (17 items) total score is >=20 points
• Patients whose score of "depressed mood" (HAM-D Item 1) is >=2 points

Exclusion Criteria

<at the start of placebo run-in phase> The patients who are meeting any of the following conditions at Week -1 (at the start of placebo run-in phase) must not be enrolled in this study.

• Patients whose primary diagnosis is a disorder classified to Axis I other than major depressive disorder in DSM-IV-TR classification (dysthymic disorder, eating disorder, specific phobia (monophobia), posttraumatic stress disorder, obsessive-compulsive disorder, panic disorder, etc.)
• Patients with a current DSM-IV-TR Axis II diagnosis that suggested non-responsiveness to pharmacotherapy or non- compliance with the protocol (e.g., antisocial or borderline personality disorder)
• Patients with a history or complication of another (non-MDD) mental disorder (schizophrenia, etc.)
• Patients with a history or complication of manic episodes
• Patients diagnosed as having an attentional deficit disorder or hyperactivity disorder
• Patients diagnosed as having a pervasive development disorder or mental retardation
• Patients diagnosed as abusing or dependent on alcohol or drug within one year before the Week -1 visit
• Patients who have undergone electroconvulsive therapy within one year before the Week -1 visit for the treatment of the current episode
• Patients who have a history of treatment with depot neuroleptics
• Patients with a history of serotonin syndrome or neuroleptic malignant syndrome
• Patients with a >= 3-point score of "suicide" (HAM-D Item 3) or patients whose Columbia Suicide Severity Rating Scale (C-SSRS) assessment suggests that they are or have been at significant risk for harming themselves or have actually harmed themselves, or who, in the opinion of the investigator (subinvestigator), are at significant risk for harming self or others.
• Patients with a history of suicide attempt, self-injurious action (excluding action with no intention of suicide) or overdosage (excluding apparently accidental overdosage)
• Patients who have taken another investigational product or a drug used in a post-marketing clinical study within 12 weeks before the Week -1 visit
• Patients with glaucoma
• Patients with a convulsive disorder such as epilepsy or a history of it
• Patients using a drug increasing an onset risk of bleeding, patients with a bleeding tendency or bleeding diathesis
• Patients complicated with severe renal or hepatic dysfunction
• Patients complicated with serious organic brain disorder
• Patients with a history or complication of cancer or malignant tumor
• Patients complicated by chronic hepatitis B or C being positive in test of hepatitis B surface antigen (HbsAg) or hepatitis C antibody
• Pregnant, lactating or possibly pregnant female patients, and female patients wishing to be pregnant during the study period
• Patients who have previously been unresponsive to paroxetine therapy (e.g. >4wks unresponsive to paroxetine for depression).
• Patients with a history of having discontinued treatment due to an adverse event caused by paroxetine
• Patients with a history of hypersensitivity to paroxetine.
• Patients judged ineligible to participate in this study by the investigator or subinvestigator

• Patients with a 3 or more-point score of "suicide" (HAM-D Item 3) or with a strong suicidal tendency by C-SSRS and investigator clinical judgement.
• Patients whose HAM-D (17 items) total score at the Week 0 visit has changed ±25 %, or exceeding the range of ±25 % of the score at the Week -1 visit
• Patients whose Drug 1 (run-in placebo) compliance rate in the period from Week -1 to Week 0 has been < 80 %
• Patients judged ineligible as the study subjects by the investigator or subinvestigator

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Aichi, , Japan

GSK Investigational Site

Aichi, , Japan

GSK Investigational Site

Aichi, , Japan

GSK Investigational Site

Chiba, , Japan

GSK Investigational Site

Fukuoka, , Japan

GSK Investigational Site

Fukuoka, , Japan

GSK Investigational Site

Fukuoka, , Japan

GSK Investigational Site

Fukuoka, , Japan

GSK Investigational Site

Fukuoka, , Japan

GSK Investigational Site

Fukuoka, , Japan

GSK Investigational Site

Fukuoka, , Japan

GSK Investigational Site

Gunma, , Japan

GSK Investigational Site

Hokkaido, , Japan

GSK Investigational Site

Hokkaido, , Japan

GSK Investigational Site

Hokkaido, , Japan

GSK Investigational Site

Hyōgo, , Japan

GSK Investigational Site

Hyōgo, , Japan

GSK Investigational Site

Hyōgo, , Japan

GSK Investigational Site

Ibaraki, , Japan

GSK Investigational Site

Kanagawa, , Japan

GSK Investigational Site

Kanagawa, , Japan

GSK Investigational Site

Kanagawa, , Japan

GSK Investigational Site

Kanagawa, , Japan

GSK Investigational Site

Kanagawa, , Japan

GSK Investigational Site

Kanagawa, , Japan

GSK Investigational Site

Kanagawa, , Japan

GSK Investigational Site

Kumamoto, , Japan

GSK Investigational Site

Kyoto, , Japan

GSK Investigational Site

Nagano, , Japan

GSK Investigational Site

Nagano, , Japan

GSK Investigational Site

Osaka, , Japan

GSK Investigational Site

Osaka, , Japan

GSK Investigational Site

Osaka, , Japan

GSK Investigational Site

Osaka, , Japan

GSK Investigational Site

Saga, , Japan

GSK Investigational Site

Saga, , Japan

GSK Investigational Site

Saitama, , Japan

GSK Investigational Site

Saitama, , Japan

GSK Investigational Site

Saitama, , Japan

GSK Investigational Site

Saitama, , Japan

GSK Investigational Site

Tochigi, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tokyo, , Japan

GSK Investigational Site

Tottori, , Japan

GSK Investigational Site

Gwangju, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

Countries

Japan; South Korea

References

Higuchi T, Hong JP, Jung HY, Watanabe Y, Kunitomi T, Kamijima K. Paroxetine controlled-release formulation in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled study in Japan and Korea. Psychiatry Clin Neurosci. 2011 Dec;65(7):655-63. doi: 10.1111/j.1440-1819.2011.02243.x. Epub 2011 Sep 6.

Reference Type: BACKGROUND

PMID: 21895859 (View on PubMed)

Study Documents

Document Type: Dataset Specification

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Document Type: Statistical Analysis Plan

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Document Type: Study Protocol

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Document Type: Annotated Case Report Form

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Document Type: Individual Participant Data Set

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Related Links

https://www.clinicalstudydatarequest.com

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Other Identifiers

112810

Identifier Type: -

Identifier Source: org_study_id